Increased Immunogenicity of an Anchor-modified Tumor-associated Antigen is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2005 Apr 9

PMID 15814707

Citations 63

Authors

Oleg Y Borbulevych

Tiffany K Baxter

Zhiya Yu

Nicholas P Restifo

Brian M Baker

Affiliations

Soon will be listed here.

Abstract

The use of "anchor-fixed" altered peptide ligands is of considerable interest in the development of therapeutic vaccines for cancer and infectious diseases, but the mechanism by which successful altered peptide ligands elicit enhanced immunity is unclear. In this study, we have determined the crystallographic structure of a major tumor rejection Ag, gp100(209-217), in complex with the HLA-A*0201 (HLA-A2) molecule, as well as the structure of a modified version of the peptide which substitutes methionine for threonine at position 2 (T2M; gp100(209-2M)). The T2M-modified peptide, which is more immunogenic in vitro and in vivo, binds HLA-A2 with a approximately 9-fold greater affinity and has a approximately 7-fold slower dissociation rate at physiological temperature. Within the limit of the crystallographic data, the T2M substitution does not alter the structure of the peptide/HLA-A2 complex. Consistent with this finding, in peripheral blood from 95 human subjects, we were unable to identify higher frequencies of T cells specific for either the native or modified peptide. These data strongly support the conclusion that the greater immunogenicity of the gp100(209-2M) peptide is due to the enhanced stability of the peptide/MHC complex, validating the anchor-fixing approach for generating therapeutic vaccine candidates. Thermodynamic data suggest that the enhanced stability of the T2M-modified peptide/HLA-A2 complex is attributable to the increased hydrophobicity of the modified peptide, but the gain due to hydrophobicity is offset considerably by the loss of a hydrogen bond made by the native peptide to the HLA-A2 molecule. Our findings have broad implications for the optimization of current vaccine-design strategies.

Citing Articles

The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.

Gray G, Chukwuma P, Eldaly B, Perera W, Brambley C, Rosales T Immunol Rev. 2025; 329(1):e13439.

PMID: 39804137 PMC: 11771984. DOI: 10.1111/imr.13439.

Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.

Tarabini R, Vieira G, Rigo M, Souza A Sci Rep. 2024; 14(1):16721.

PMID: 39030304 PMC: 11271619. DOI: 10.1038/s41598-024-67099-2.

Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement.

Hopkins J, MacLachlan B, Harper S, Sewell A, Cole D Discov Immunol. 2024; 1(1):kyac001.

PMID: 38566908 PMC: 10917088. DOI: 10.1093/discim/kyac001.

APE-Gen2.0: Expanding Rapid Class I Peptide-Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries.

Fasoulis R, Rigo M, Lizee G, Antunes D, Kavraki L J Chem Inf Model. 2024; 64(5):1730-1750.

PMID: 38415656 PMC: 10936522. DOI: 10.1021/acs.jcim.3c01667.

Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines.

Yue C, Wang P, Tian J, Gao G, Liu K, Liu W Int J Biol Sci. 2023; 19(13):4052-4060.

PMID: 37705735 PMC: 10496500. DOI: 10.7150/ijbs.80468.

References

McRee D . XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. J Struct Biol. 1999; 125(2-3):156-65. DOI: 10.1006/jsbi.1999.4094. View

Irvine K, Parkhurst M, Shulman E, Tupesis J, Custer M, Touloukian C . Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res. 1999; 59(11):2536-40. PMC: 2249691. View

Ding Y, Baker B, Garboczi D, Biddison W, Wiley D . Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity. 1999; 11(1):45-56. DOI: 10.1016/s1074-7613(00)80080-1. View

Gakamsky D, Boyd L, Margulies D, Davis D, Strominger J, Pecht I . An allosteric mechanism controls antigen presentation by the H-2K(b) complex. Biochemistry. 1999; 38(37):12165-73. DOI: 10.1021/bi9905821. View

Kuhns J, Batalia M, Yan S, Collins E . Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J Biol Chem. 1999; 274(51):36422-7. DOI: 10.1074/jbc.274.51.36422. View

Kirksey T, Frelinger J, Collins E . The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes. J Biol Chem. 1999; 274(52):37259-64. DOI: 10.1074/jbc.274.52.37259. View

Khan A, Baker B, Ghosh P, Biddison W, Wiley D . The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J Immunol. 2000; 164(12):6398-405. DOI: 10.4049/jimmunol.164.12.6398. View

Gakamsky D, Davis D, Strominger J, Pecht I . Assembly and dissociation of human leukocyte antigen (HLA)-A2 studied by real-time fluorescence resonance energy transfer. Biochemistry. 2000; 39(36):11163-9. DOI: 10.1021/bi000763z. View

Baker B, Gagnon S, Biddison W, Wiley D . Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity. 2000; 13(4):475-84. DOI: 10.1016/s1074-7613(00)00047-9. View

10.

Slansky J, Rattis F, Boyd L, Fahmy T, Jaffee E, Schneck J . Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 2000; 13(4):529-38. DOI: 10.1016/s1074-7613(00)00052-2. View

11.

Kersh G, Miley M, Nelson C, Grakoui A, Horvath S, Donermeyer D . Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol. 2001; 166(5):3345-54. DOI: 10.4049/jimmunol.166.5.3345. View

12.

Sharma A, Kuhns J, Yan S, Friedline R, Long B, Tisch R . Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts. J Biol Chem. 2001; 276(24):21443-9. DOI: 10.1074/jbc.M010791200. View

13.

Hillig R, Coulie P, Stroobant V, Saenger W, Ziegler A, Hulsmeyer M . High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene. J Mol Biol. 2001; 310(5):1167-76. DOI: 10.1006/jmbi.2001.4816. View

14.

Sliz P, Michielin O, Cerottini J, Luescher I, Romero P, Karplus M . Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol. 2001; 167(6):3276-84. DOI: 10.4049/jimmunol.167.6.3276. View

15.

Wang Z, Turner R, Baker B, Biddison W . MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors. J Immunol. 2002; 169(6):3146-54. DOI: 10.4049/jimmunol.169.6.3146. View

16.

Denkberg G, Klechevsky E, Reiter Y . Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J Immunol. 2002; 169(8):4399-407. DOI: 10.4049/jimmunol.169.8.4399. View

17.

Binz A, Rodriguez R, Biddison W, Baker B . Thermodynamic and kinetic analysis of a peptide-class I MHC interaction highlights the noncovalent nature and conformational dynamics of the class I heterotrimer. Biochemistry. 2003; 42(17):4954-61. DOI: 10.1021/bi034077m. View

18.

Rosenberg S, Yang J, Schwartzentruber D, Hwu P, Topalian S, Sherry R . Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2003; 9(8):2973-80. PMC: 2259234. View

19.

Gagnon S, Wang Z, Turner R, Damirjian M, Biddison W . MHC recognition by hapten-specific HLA-A2-restricted CD8+ CTL. J Immunol. 2003; 171(5):2233-41. DOI: 10.4049/jimmunol.171.5.2233. View

20.

Biddison W, Turner R, Gagnon S, Lev A, Cohen C, Reiter Y . Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. J Immunol. 2003; 171(6):3064-74. DOI: 10.4049/jimmunol.171.6.3064. View